Review opinions of the board of supervisors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
Joincare Pharmaceutical Group Industry Co.Ltd(600380) board of supervisors
Review opinions on the proposal of the ninth meeting of the eighth board of supervisors of the company
The company held the 9th meeting of the 8th board of supervisors on Friday, April 22, 2022, which mainly considered the relevant proposals such as the second phase of the shareholding plan of the company’s supervisors and medium and long-term business partners’ shareholding plan. Now, the board of supervisors of the company has issued the following review opinions on the relevant proposals:
1、 Review opinions on the proposal on nominating Mr. Xing Zhiwei as a supervisor candidate of the board of supervisors
The board of supervisors of the company believes that Mr. Xing Zhiwei’s qualification meets the relevant provisions of the company law and the articles of association, and there is no situation that he is not allowed to serve as a supervisor of the company as stipulated in the company law and the articles of association, and there are no other circumstances that Shanghai stock exchange determines that he is not suitable to serve as a supervisor of a listed company.
The board of supervisors of the company agreed that he was a candidate for supervisor of the eighth board of supervisors of the company and submitted it to the general meeting of shareholders of the company for deliberation.
2、 Review opinions on the company’s phase II shareholding plan of medium and long term business partner shareholding plan (Draft) and its summary
The board of supervisors of the company believes that:
1. The company’s second phase shareholding plan (Draft) of medium and long term business partner shareholding plan (hereinafter referred to as the plan) and its abstract comply with the company law, the securities law, the guiding opinions on the pilot implementation of employee stock ownership plan by listed companies (hereinafter referred to as the Guiding Opinions), the guidelines for self discipline supervision of listed companies on Shanghai Stock Exchange No. 1 – standardized operation and other relevant laws, administrative regulations Regulations, normative documents and relevant provisions of the articles of association do not prohibit the implementation of the ESOP as stipulated in the guiding opinions and other relevant laws, administrative regulations, rules and normative documents.
2. There is no situation that employees are forced to participate in the plan by means of apportionment or forced distribution, nor is there any plan or arrangement for the company to provide loans, loan guarantees or any other financial assistance to the holders of the plan. 3. The implementation of this plan will not harm the interests of the company and all shareholders and meet the needs of the company’s long-term development. 4. The implementation of this plan by the company will help to realize the company’s development concept and effectively stimulate the entrepreneurial spirit of the company’s senior managers. By giving rights and obligations to the holders and establishing a partnership mechanism of “benefit sharing and risk sharing” for business partners, the company will effectively promote and promote the transformation of the company’s “manager” to “partner” identity, and gather a group of era fighters and business leaders with common values, Carry forward entrepreneurship, realize the sustainable development of the company and ensure the achievement of the company’s development goals.
5. Before the implementation of the plan, the company has fully solicited the opinions of employees through the employee congress and reviewed relevant issues
Review opinions of the board of supervisors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
Procedures and decisions are legal and effective.
3、 Audit opinions on the company’s report for the first quarter of 2022
The board of supervisors of the company believes that the preparation and review procedures of the company’s first quarter report in 2022 comply with relevant laws and regulations, the articles of association and the provisions of the company’s internal management system, the content and format of the first quarter report comply with the provisions of the CSRC and Shanghai Stock exchange, and the information contained can truly and completely reflect the company’s operation, management and financial status in the first quarter of 2022 in all aspects, The personnel involved in the preparation and review of the first quarter report did not violate the confidentiality provisions.
Joincare Pharmaceutical Group Industry Co.Ltd(600380) April 22, 2002
